Want to join the conversation?
In addition to AKN-083, $AGN's Akarna acquisition also includes a portfolio of some development-stage farnesoid X receptor compounds. AKN-083 is complementary to Cenicriviroc and Evogliptin, the development compounds of Tobira Therapeutics the acquisition of which was also announced on Sept. 20.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?